Zenas BioPharma (ZBIO) Other Non-Current Liabilities (2023 - 2026)
Zenas BioPharma (ZBIO) recorded quarterly Other Non-Current Liabilities of $84.9 million in Q1 2026, up 7.97% quarter-over-quarter from $78.6 million in Q4 2025.
Zenas BioPharma (ZBIO) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Zenas BioPharma's Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $84.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $84.9 million; the TTM figure through Mar 2026 stood at $84.9 million (changed N/A YoY), while the FY2025 annual figure was $78.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $84.9 million for Q1 2026 at Zenas BioPharma, up from $78.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $84.9 million in Q1 2026 to a low of $20.3 million in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $61.3 million across 3 years, with a median of $78.6 million in 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Zenas BioPharma | 1.10 Bn | 379.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.90 Mn |
| Dec 31, 2025 | 78.64 Mn |
| Dec 31, 2023 | 20.30 Mn |